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ABSTRACT
ISG15 is a diubiquitin-like modifier and one of the most rapidly induced genes upon type I interferon stimulation. Hundreds of
host proteins and a number of viral proteins have been shown to be ISGylated, and understanding how these modifications af-
fect the interferon response and virus replication has been of considerable interest. ISG15/mice exhibit increased susceptibil-
ity to viral infection, and in the case of influenza B virus and vaccinia virus, ISG15 conjugation has been shown to restrict virus
replication in vivo. A number of studies have also found that ISG15 is capable of antagonizing replication of some viruses in tis-
sue culture. However, recent findings have demonstrated that ISG15 can protect mice from Chikungunya virus infection without
affecting the virus burden. In order to better understand the function of ISG15 in vivo, we characterized the pathogenesis of in-
fluenza A virus and Sendai virus in ISG15/mice. We found that ISG15 protects mice from virus induced lethality by a conju-
gation-dependent mechanism in both of these models. However, surprisingly, we found that ISG15 hadminimal effect on virus
replication and did not have an obvious role in the modulation of the acute immune response to infection. Instead, we observed
an increase in the number of diseased small airways in mice lacking ISG15. This ability of ISG15 to protect mice in a conjugation-
dependent, but nonantiviral, manner from respiratory virus infection represents a previously undescribed role for ISG15 and
demonstrates the importance of further characterization of ISG15 in vivo.
IMPORTANCE
It has previously been demonstrated that ISG15/mice are more susceptible to a number of viral infections. Since ISG15 is one
of the most strongly induced genes after type I interferon stimulation, analysis of ISG15 function has largely focused on its role
as an antiviral molecule during acute infection. Although a number of studies have shown that ISG15 does have a small effect on
virus replication in tissue culture, few studies have confirmed this mechanism of protection in vivo. In these studies we have
found that while ISG15/mice are more susceptible to influenza A virus and Sendai virus infections, ISGylation does not ap-
pear to mediate this protection through the direct inhibition of virus replication or the modulation of the acute immune re-
sponse. Thus, in addition to showing a novel mode of ISG15mediated protection from virus infection, this study demonstrates
the importance of studying the role of ISG15 in vivo.
During acute infection, the survival of an organism is depen-dent on both its ability to inhibit pathogen replication, thus
reducing pathogen burden, and its ability to tolerate the ensuing
tissue damage incurred both from the pathogen itself, as well as
from the immune response mounted against the pathogen (1, 2).
Limiting pathogen replication and eventual pathogen clearance is
dependent on both the innate and the adaptive immune re-
sponses. Of the many genes induced after viral infection, type I
interferons are among the most rapidly and robustly expressed
genes and play a critical role in modulating the immune response
to viral infections (3–5).
After detection of viruses through pathogen recognition recep-
tors, type I interferons are released from cells and subsequently
bind to their cell surface receptors (IFNAR1/IFNAR2) in both an
autocrine and paracrine fashion. Signaling through the type I in-
terferon receptors induces the expression of hundreds of genes
classified as interferon-stimulated genes (ISGs). A subset of ISGs
directly inhibit different steps of virus replication, and it is
through the collective action of these ISGs that type I interferons
convert cells into what has classically been described as an antiviral
state (6). In addition, type I interferons play a role in the regula-
tion of both innate and adaptive immune cell responses to infec-
tion (7). These include their ability to induce natural killer (NK)
cell activation, enhance antigen presentation activity by dendritic
cells and aid in the development and maintenance of CD8 T cell
memory, and antibody responses. Therefore, type I interferons
regulate a range of host responses that impact disease outcome.
Interferon-stimulated gene 15 (ISG15) is one of the most rap-
idly and robustly induced genes upon type I interferon stimula-
tion (8, 9). ISG15 is an ubiquitin-like modifier containing two
ubiquitin-like domains that share ca. 30% amino acid sequence
homology to ubiquitin. ISG15 is expressed as a 17-kDa precursor
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protein that is proteolytically processed at its C terminus to expose
an LRLRGG amino acid motif through which it covalently conju-
gates to lysine residues of target proteins (10, 11). ISGylation of
target proteins occurs through an enzymatic cascade similar to
that of ubiquitin conjugation, involving an E1 activating enzyme,
an E2 conjugating enzyme, and an E3 ligase (12–17). Proteomic
studies have identified hundreds of proteins as being ISGylated
after interferon stimulation or capable of being ISGylated in an
overexpression system (18, 19). However, the effects of relatively
few of these modifications have been studied, and it remains un-
clear what the functional consequence of ISGylation is for most
ISGylated targets.
To date, the most striking phenotype that has been described in
ISG15-deficient mice is their increased susceptibility to viral in-
fections, ranging from influenza viruses to herpes simplex virus 1
(HSV-1), Chikungunya virus (CHIKV), vaccinia virus, and Sind-
bis virus (20–23). Consequently, ISG15 has been hypothesized to
protect the host from virus-induced lethality by acting as an anti-
viral molecule and directly inhibiting viral replication. Indeed,
initial studies into the mechanism by which ISG15 mediates pro-
tection supported a role for ISG15 in directly antagonizing the
virus life cycle. We have shown that influenza B virus replicates to
100-fold-greater levels in the lungs of ISG15/ deficient mice
compared to WT mice (21). This inhibition of replication was
dependent on the ability of ISG15 to form conjugates as increased
influenza B virus replication was also seen in mice that lack the
ISG15 E1 activating enzyme, UbE1L, and thus fail to form ISG15
conjugates (24). Subsequent studies have demonstrated that
ISG15 can antagonize the replication of vaccinia virus, influenza A
virus, Sendai virus, human papillomavirus, Ebola virus, and
HIV-1 in tissue culture to various degrees (23, 25–33).
However, recent evidence has shown that the role of ISG15
during infection is not limited to conjugation-dependent inhibi-
tion of virus replication. The nonconjugated (“free”) form of
ISG15 protects mice against CHIKV by regulating cytokine pro-
duction during infection. In this model, ISG15/, but not
UbE1L/, neonatal mice were found to be more susceptible than
wild-type (WT) mice to CHIKV-induced lethality, and yet no dif-
ference in viral burden was observed between ISG15/,
UbE1L/, and WT mice (22). In addition, ISG15 was not found
to affect CHIKV replication in tissue culture. Recent reports have
also confirmed that extracellular free ISG15 can activate NK cells
in vitro and augment the expression of gamma interferon in re-
sponse to Mycobacterium, providing further evidence for an im-
portant biological role for free ISG15 during infection (34–36).
These findings demonstrate that a more detailed characterization
of the in vivo function of ISG15 during viral infection is warranted.
In this study we sought to determine whether inhibition of
virus replication was a common mechanism by which ISG15 pro-
tects mice from respiratory virus infections. We found that both
ISG15/ and UbE1L/ mice exhibited increased susceptibility
to lethality induced by both influenza A virus and Sendai virus
infections, demonstrating that this protection requires ISG15
conjugation. However, unlike what we have observed during in-
fluenza B virus infection, this protection did not appear to be
mediated through the direct inhibition of virus replication. We
also did not observe significant alterations in the cytokine re-
sponse or the recruitment of inflammatory cells to the lungs after
infection. Together, these results provide further evidence that
ISG15 can protect the host from viral infection by mechanisms
that extend beyond the regulation of viral replication.
MATERIALS AND METHODS
Mice.Mice were bred and maintained at Washington University School of
Medicine in accordance with all federal and university guidelines, under
specific-pathogen-free conditions. WT C57BL/6J mice were purchased
from Jackson Laboratory (Bar Harbor, ME) and bred and maintained in
our facilities. ISG15/ mice (provided by Klaus-Peter Knobeloch, Uni-
versity Clinic Freiburg, Germany) and UbE1L/ mice (provided by
Dong-Er Zhang, University of California, San Diego, CA) were generated
as previously described (37, 38). ISG15/ and UbE1L/mice were fully
backcrossed (99.72 and 99.93%, respectively, to C57BL/6 by congenic
SNP analysis through Taconic Laboratories (Hudson, NY).
Viruses. (i) Influenza A virus. Recombinant influenza A/WSN/33
(rWSN) virus was generated from cDNA as previously described (39). The
virus was grown on MDCK cells using Dulbecco modified Eagle medium
(DMEM) containing 1 g/ml N-acetyltrypsin (Sigma Chemicals, St.
Louis, MO), 100 U/ml penicillin, and 100 g/ml streptomycin (Invitro-
gen, Carlsbad, CA). The cells were infected at a multiplicity of infection of
0.01 PFU/cell. Cell culture medium was harvested at 48 h postinfection
and centrifuged to remove cell debris, and titers were determined by
plaque assay in MDCK cells.
(ii) Influenza B virus. Recombinant WT influenza B/Yamagata/88
virus was grown in 10-day-old embryonated chicken eggs. Virus titers
from allantoic fluid were determined by plaque assay in MDCK cells.
(iii) Sendai virus. Sendai/52 Fushimi strain virus was purchased from
the American Type Culture Collection. Virus was plaque purified after
infection of Vero cells to isolate a single clone that was then propagated in
11-day-old embryonated chicken eggs. Virus from allantoic fluid was di-
luted in phosphate-buffered saline (PBS) and stored at 80°C. Titers of
viral stocks were determined by plaque assay in Vero cells.
Virus growth curves. Murine tracheal epithelial cultures were gener-
ated from the different genotypes of mice as previously described (40).
Cells were harvested from the tracheas of female mice (5 to 12 weeks old)
and grown under media in transwells (Corning) for 7 days. The apical
medium was then removed, and the cells were grown at the air-liquid
interface for 2 to 3 weeks prior to experimentation. For viral growth
curves, virus was diluted in DMEM supplemented with 1% penicillin–1%
streptomycin [DMEM(1%P/S)] to concentrations such that the indicated
PFU were administered in volumes of 100 l. Infections were performed
by adding 100l of virus to the apical chamber and incubation at 37°C for
1 h. The virus was removed, and the apical chamber was washed three
times with 200 l of DMEM(1%P/S). After a washing step, 100 l of
DMEM(1%P/S) was added back to the apical chamber. At the indicated
times, the apical medium was collected and replaced with 100 l of
DMEM(1%P/S). Virus titers in apical media were assessed by plaque assay
on MDCK cells. For the beta interferon pretreatment conditions, beta
interferon (PBL Assay Science) was added to basolateral media. After 24 h,
immediately prior to infection, the basolateral media was removed, and
the basolateral chambers were washed twice with PBS and then replaced
with medium containing no interferon. The beta interferon doses and the
viral infectious doses were different for each virus, as follows: influenza A
virus, 50 U of beta interferon and 9 104 PFU; Sendai virus, 15 U of beta
interferon and 9 105 PFU; and influenza B virus, 15 U of beta interferon
 and 9 105 PFU.
In vivo infections. Mice were anesthetized using an intraperitoneal
injection of a ketamine-xyline cocktail prior to infection. For influenza A
virus infections, 6- to 8-week-old female mice were intranasally (i.n.)
infected with 5,000 PFU of influenza A/WSN/33 virus in 25l of PBS. For
Sendai virus infections, 8- to 10-week-old male mice were infected i.n.
with 1.2 106 PFU of Sendai virus in a total volume of 30 l of PBS for
Fig. 2 to 5. For the experiments performed in Fig. 6 to assess lung repair,
mice were infected with a dose (0.6 to 1.0 106 PFU) that reduced lethal-
ity to20% in the infected ISG15/ mice.
Morales et al.
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Lung viral load assessment. To assess lung titers, the right superior,
middle, and inferior lobes were collected in 1 ml of PBS. Lungs were
homogenized in a Roche MagNA Lyser using 1.0-mm-diameter zirconia/
silica beads (BioSpec Products). The titers of lung homogenates were
assessed by plaque assay using MDCK cells for influenza A virus and Vero
cells for Sendai virus.
Infiltrating cell analysis. (i) Bronchoalveolar lavage analysis. Bron-
choalveolar lavage fluid (BALF) was collected by inserting a catheter into
the trachea and flushing 800 l of PBS into and out of the lungs three
times (600 l recovered). Lavages were centrifuged at a 2.5 relative
centrifugal force for 5 min to pellet the cells. The supernatant was col-
lected and analyzed for cytokines. Cells collected from lavages were resus-
pended in fluorescence-activated cell sorting (FACS) buffer (PBS, 3%
bovine serum albumin, 0.1% sodium azide). BALF cells were counted by
using a hemocytometer, and then cells from mice of the same genotype
were pooled for further analysis. Red blood cells (RBCs) were lysed in 200
l of RBC lysis buffer (Sigma) for 5 min at room temperature. The cells
were washed in FACS buffer and incubated in FcR block for 30 min. The
cells were then stained in different mixes of antibodies against cell surface
markers for 30 min, washed three times in FACS buffer, fixed in 1%
formaldehyde, and analyzed by flow cytometry (BD FACSCanto).
(ii) Lung homogenates. To analyze infiltrating cells in the lung paren-
chyma, the left lung was collected from a lavaged mouse. The lung was
minced with scissors and incubated in DMEM with 350 U/ml collagenase
type I (Worthington) and 50 U/ml DNase (Worthington) for 1 h at 37°C.
The remaining tissue after enzymatic digestion was crushed between the
rough edge of a frosted microscope slide. The cells were passed through a
cell strainer. RBCs were lysed in 1 ml of RBC lysis buffer (Sigma) for 5 min
at room temperature. The cells were then washed with FACS buffer,
blocked, stained, and analyzed as described above for BALF cells.
Total lung and lavage cell counts were determined by counting cells
that excluded trypan blue using a hemocytometer. The cell count data for
each time point were collected from infected WT mice (6 to 9 mice, col-
lected from 3 to 4 independent infections), ISG15/ mice (6 to 8 mice,
collected from 3 to 4 independent infections), and UbE1L/mice (5 to 8
mice, collected from 2 to 3 independent infections). Cell counts from
mock-infected lungs (2 mice per genotype collected from 2 independent
experiments) and BALF (5 to 6 mice collected from 5 independent exper-
iments) were pooled from various times after mock infection since cell
counts did not differ between days after mock infection.
Data in flow cytometry analysis of cell types represent a total of 6 to 8
mice collected from 3 independent experiments for WT and ISG15/
mice, and 5 to 8 total mice collected from 2 to 3 experiments for
UbE1L/mice, per time point. Cell populations were defined as follows:
neutrophils (Cd11b Ly6G MHCII), Inflammatory monocytes
(Cd11b Ly6G Ly6Cint MHC-IIint Cd11cint), NK cells (CD3NK1.1),
CD8 T cells (CD3 CD8), CD4 T cells (CD3 CD4), and B cells
(CD19).
Antibodies. The following antibodies were purchased from eBiosci-
ence: fluorescein isothiocyanate (FITC)-conjugated anti-MHC-II (M5/
114.15.2), allophycocyanin-conjugated (APC) anti-B220 (RA3-682),
PERCP-Cy5.5 anti-CD11b (M1/70), and PERCP-Cy5.5 anti-CD3ε (145-
2C11). The following antibodies were purchased from BioLegend: FITC-
conjugated anti-CD8 (53-6.7), phycoerythrin (PE)-conjugated anti-Ly6G
(1A8), PE-conjugated anti-CD19 (6D5), APC-conjugated anti-CD11c
(N418), and Pacific Blue-conjugated anti-Ly6c (HK1.4). The following
antibodies were purchased from BD Biosciences: PE-conjugated anti-
CD4 (GK1.5) and APC-conjugated anti-NK1.1 (PK136).
Cytokine analysis. BALF was collected as described above and ana-
lyzed using Bio-Rad Bio-Plex analysis according to the manufacturer’s
instructions. Quantification of alpha interferon in BALF was performed
using a pan-alpha-interferon enzyme-linked immunosorbent assay
(ELISA; PBL Assay Science).
Sendai virus. Data from all time points were generated from 6 to 8
mice collected from 3 separate infections, except for the UbE1L/ day 3
data, which were generated from 5 mice from 2 infections. Cytokine anal-
ysis of mock-infected mice was generated from 2 mice of each genotype
for days 3 and 6 after mock infection (intranasal PBS instillation), and one
mouse from each genotype for day 8 after mock infection. Analytes in
mock-infected BALF did not vary between genotype or day after mock
infection; thus, all mock values were pooled.
Influenza A virus. WT and ISG15/ data were generated from 5 to 6
mice from 1 to 2 experiments per time point. UbE1L/ data were gen-
erated from 3 to 4 mice from one experiment per time point. Mock infec-
tion data were generated from 4 to 6 mice from 2 to 3 experiments per
time point. No differences were detected between any genotype at any
time points; thus, all mock values were pooled.
Histology. For lung histological analysis, mice were infected as de-
scribed above and sacrificed at the indicated times postinfection. Either
the left lobe was inflated with 500 l of formalin or all lobes were inflated
with 1.0 ml of formalin. Lungs were removed and incubated in a 50-ml
conical tube containing 15 ml of formalin. After 36 to 48 h in formalin,
lungs were washed for 15 min in serial washes using PBS, 30% ethanol,
and 50% ethanol and then stored in 70% ethanol until they were pro-
cessed for paraffin embedding, sectioning, and staining. Lung sections
were stained with hematoxylin and eosin and scored blindly by a pathol-
ogist (T.S.S.). An average of 52.8 small airways (100 to 300 m in diame-
ter) were scored per mouse (range, 33 to 89; median, 46).
Statistics. All data were analyzed using Prism software (GraphPad,
San Diego, CA). Statistical analyses used for particular experiments are
indicated in figure legends. Error bars in all figures represent the standard
errors of the mean.
RESULTS
ISG15 functions in a conjugation-dependentmanner to protect
mice from influenza A virus-induced lethality without altering
viral loads. We previously showed that ISG15 contributes to the
host response against both influenza A virus and influenza B virus,
since ISG15/ mice exhibit increased lethality after infection
compared to WT mice (21). ISG15-mediated protection against
influenza B virus infection is dependent upon ISG15 conjugation
and results in a dramatic reduction in viral loads in vivo (24). To
determine whether the protective activity of ISG15 during influ-
enza A virus infection was also dependent upon conjugation, we
infected WT, ISG15/, and UbE1L/ mice with 5.0 103 PFU
of influenza A/WSN/33 virus i.n. and monitored the mice for le-
thality. As expected, ISG15/ mice displayed increased lethality
compared to WT mice (Fig. 1A). This protection mediated by
ISG15 appeared to be largely conjugation dependent, since
UbE1L/ mice also displayed increased lethality compared to
WT mice (Fig. 1A). Interestingly, despite the large difference in
survival, the extent of weight loss in both ISG15/ and
UbE1L/ mice was similar to the weight loss observed in WT
mice through 9 days postinfection, after which both ISG15/ and
UbE1L/ mice began to succumb to infection (Fig. 1B). This
observation is strikingly different from what we previously re-
ported for influenza B virus infection, where increased mortality
in both ISG15/ and UbE1L/ mice was associated with a dra-
matic increase in weight loss compared to WT mice (24).
The increased lethality we previously observed in ISG15/
mice during influenza B virus infection was also accompanied by a
2- to 3-log increase in virus titers at days 3 and 6 postinfection
compared to WT mice (24). To determine whether ISG15 played
a similar role during influenza A virus infection, we next evaluated
viral loads within the lungs of infected mice during the course of
infection. Virus could be detected in the lung 1 day postinfection,
with all three genotypes of mice displaying similar virus titers
ISG15 Protection from Inﬂuenza A and Sendai Viruses
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(Fig. 1C). Peak virus titers were reached by 3 days postinfection,
but despite the increased lethality observed in both ISG15/ and
UbE1L/mice, we observed similar viral loads in all mice at both
days 3 and 6 postinfection. On day 8 postinfection the lung titers
were still similar between the three genotypes as the mice began to
clear the virus. Staining lung sections with an anti-influenza A
virus polyclonal serum revealed a similar pattern of staining and
clearance of the bronchiolar and alveolar epithelium in both WT
and ISG15/ mice (data not shown). These results suggest that
during influenza A virus infection ISG15 protects the host from
lethality in a conjugation-dependent manner that is independent
of its previously reported effects on viral replication.
ISG15 also protectsmice fromSendai virus induced lethality
in a conjugation-dependentmannerwithminimal impact upon
viral loads. We next wanted to determine whether increased le-
thality in ISG15/ mice without a concomitant increase in viral
load was unique to influenza A virus infection. We chose to eval-
uate the pathogenesis of Sendai virus (a mouse paramyxovirus) in
ISG15/ mice, since it is a natural mouse pathogen. We infected
WT, ISG15/, and UbE1L/ mice i.n. with 1.2  106 PFU of
Sendai virus and monitored the animals for weight loss and lethal-
ity. We found that ISG15 protected mice from Sendai virus-in-
duced lethality in a conjugation-dependent manner. In WT mice,
infection induced significant disease with a ca. 25% weight loss but
was rarely lethal (Fig. 2A and B). In contrast, nearly 70% of the
ISG15/ and UbE1L/ mice succumbed to infection by day 10
postinfection despite exhibiting weight loss similar to that of WT
controls (Fig. 2B). We next evaluated viral loads in the lungs of
these mice during the course of Sendai virus infection. Once again,
unlike the 2- to 3-log increases in viral replication that we ob-
served during influenza B virus infection, we noted minimal dif-
ferences in viral loads between the three genotypes during the
course of Sendai virus infection. In all three genotypes of mice,
peak viral loads were reached at 3 days postinfection, with no
differences noted between the genotypes (Fig. 2C). At 6 days
postinfection there was a small,3-fold, increase in viral loads in
the ISG15/ and UbE1L/mice compared to WT mice. By day
8 postinfection, all three genotypes of mice had started to clear the
virus, and we observed no difference in viral loads between WT
and ISG15/ mice, although we did detect increased viral bur-
dens in the UbE1L/ mice. Staining for viral antigen using an
anti-Sendai virus polyclonal serum revealed no differences in viral
spread during the course of infection between WT and ISG15/
mice (data not shown). Thus, ISG15 protected mice from Sendai
virus-induced lethality in a conjugation-dependent manner while
having only a minimal impact upon viral burden over the course
of the infection.
ISG15 does not affect influenza A virus or Sendai virus repli-
cation in vitro. Although we did not observe a major difference
between influenza A virus or Sendai virus burden in ISG15/ and
WT mice, it has been previously reported that ISG15 conjugation
can antagonize both influenza A virus and Sendai virus replication
in human cell lines. Small interfering RNA (siRNA) knockdown of
ISG15 or HERC5 in HEK293 cells resulted in increased Sendai
virus replication (28). Similarly, siRNA knockdown of ISG15 or
HERC5 in A549 cells or ISG15 and UbE1L in Calu3 cells resulted
in ca. 5- to 10-fold increases in influenza A virus replication (25,
27). Given these previous findings, and the fact that we did see a
small increase in Sendai virus titers in ISG15/ mice at day 6
postinfection, we wanted to more carefully evaluate whether
ISG15 can directly impact viral replication in the mouse model.
To this end, we generated primary murine trachea epithelial cells
(mTECs) from WT, ISG15/, and UbE1L/ mice and evalu-
ated influenza A virus and Sendai virus growth in these cells.
First, we infected mTECs with influenza B virus to determine
whether these cultures could recapitulate the increase in virus rep-
FIG 1 ISG15 protection against influenza A virus is conjugation dependent but not antiviral. WT, ISG15/, and UBE1L/mice were infected with 5.0 103
PFU of influenza A/WSN/33 i.n. Mice were monitored for lethality (A) and weight loss (B), or they were sacrificed at the indicated times postinfection, and viral
loads in the lungs were assessed by plaque assay (C). For vial load assessment, the numbers of mice analyzed per genotype at each time point are indicated in
parentheses. Lung titer samples were collected from 1 to 6 independent experiments. Panel A: *, P	 0.05, Mantel-Cox test. Panel B: *, P	 0.05, Kruskal-Wallis,
followed by Dunn’s posttest was performed for each time point.
Morales et al.
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lication observed in vivo in ISG15/ mice. In cultures that were
not pretreated with interferon, a small but statistically significant
increase in influenza B virus replication was observed at late time
points in mTECs derived from ISG15/mice (Fig. 3A). The pre-
treatment of cultures with beta interferon for 24 h prior to infec-
tion, in order to induce ISG15 expression and conjugation, re-
sulted in a 33-fold increase in replication in the ISG15/ cells
(Fig. 3B). Next, we assessed the replication of influenza A virus
and Sendai virus in mTECs lacking ISG15 or UbE1L. In untreated
mTECs both influenza A virus and Sendai virus grew with similar
kinetics in WT, ISG15/, and UbE1L/ cells (Fig. 3C and E).
We then pretreated the mTEC cultures with a dose of beta inter-
feron that induced ISG15 conjugation and resulted in100-fold
inhibition of virus replication in WT mTECs at 24 to 36 h postin-
fection. However, even after interferon stimulation we observed no
difference in the replication of either influenza A virus or Sendai virus
in any of the three genotypes of mTECs (Fig. 3D and F). These results,
together with our in vivo virus titer data, suggest that during both
influenza A virus and Sendai virus infection ISG15 does not directly
inhibit virus replication within infected cells and therefore appears to
protect the host from lethality by a mechanism that is distinct from its
role during influenza B virus infection.
The loss of ISG15doesnot alter the cytokine responseduring
influenza A virus or Sendai virus infection. We have recently
reported that increased lethality in ISG15/ mice after CHIKV
infection results from a cytokine storm and not from an inability
to control virus replication (22). We therefore wanted to evaluate
whether ISG15 regulation of the cytokine response to infection
might be responsible for the increased lethality in ISG15/ mice
after influenza A virus or Sendai virus infection.
We infected WT, ISG15/, and UbE1L/ mice with influ-
enza A virus and at days 3, 6, and 8 postinfection mice were sacri-
ficed to collect BALF. We then evaluated a panel of 10 proinflam-
matory cytokines in the BALF. The levels of all cytokines evaluated
peaked at 6 days postinfection and were either not detectable or
were greatly reduced by day 8 postinfection (Fig. 4A). We ob-
served very few statistically significant differences in cytokine lev-
els. Importantly, for the two cytokines that we did observe differ-
ences (IL-6 and RANTES), these differences were not consistently
seen in ISG15/ and UbE1L/ mice.
We performed a similar analysis of BALF cytokines during
Sendai virus infection. Once again, all cytokines analyzed were
induced above mock infection levels in all three genotypes of mice
(Fig. 4B). Similar to what we observed during influenza A virus
infection, no dramatic differences were observed in the overall
BALF cytokine response between WT, ISG15/, or UbE1L/
mice after Sendai virus infection, and any differences that were
seen were not consistent between ISG15/and UbE1L/ mice
(Fig. 4B).
Finally, we evaluated using ELISA the alpha interferon levels in
BALF from Sendai virus-infected mice. We observed no difference
in alpha interferon production in WT, ISG15/, or UbE1L/
mice at any time after Sendai virus infection (Fig. 4C). Total alpha
interferon levels peaked at 3 days postinfection, similar to the
virus titers in the lungs, and diminished over the course of infec-
tion. Overall, the ISG15/ and UbE1L/ mice appear to pro-
duce a normal interferon and cytokine response during both in-
fluenza A virus and Sendai virus infection, unlike the global
cytokine misregulation observed in ISG15/ mice during
CHIKV infection (22).
FIG 2 ISG15 protects against Sendai virus induced lethality by a conjugation-dependent mechanism but has no major effect on virus loads. WT, ISG15/, and
UBE1L/mice were infected with 1.2 106 PFU of Sendai virus i.n. and monitored for (A) lethality and (B) weight loss, or were sacrificed at the indicated times
postinfection and viral loads in the lungs were assessed by plaque assay (C). For vial load assessment, the numbers of mice analyzed per genotype at each time
point are indicated in parentheses. Lung titer samples were collected from 2 to 6 experiments. Weight loss data were compiled from 7 to 11 independent infections
of mice, some of which were sacrificed prior to day 8. The data are composed of 28 to 45 mice per genotype through day 6, 23 to 37 mice per genotype through
day 8. Panel A: *, P	 0.05, Mantel-Cox test. Panel C: *, P	 0.05, Kruskal-Wallis test, followed by Dunn’s posttest was performed for each time point.
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Similar immunecell populations are recruited to the lungs in
WT, ISG15/, and UbE1L/mice during Sendai virus infec-
tion. Much of the tissue damage incurred after respiratory virus
infection is believed to be a result of immunopathology induced in
response to the virus (41, 42). Although neutrophils and inflam-
matory macrophages are necessary for the control of virus repli-
cation, it is thought that excessive recruitment of these cell types
can lead to excessive damage of the lung resulting in mortality
(43–46). We therefore next evaluated the cellular recruitment to
the lungs of ISG15/ mice during Sendai virus and influenza A
virus infections.
An analysis of gross lung histopathology from infected mice
revealed no obvious difference in the degree of inflammation be-
tween all three genotypes of mice after either influenza A virus or
Sendai virus infection (data not shown). To evaluate this quanti-
tatively, we infected mice with Sendai virus and, at various times
postinfection, we analyzed the total number of cells recovered
from lung parenchyma digests and BALF. We observed no major
differences in the total number of cells collected from the lung
parenchyma or BALF of WT, ISG15/, or UBE1L/ mice after
infection (Fig. 5A and B). We also observed no difference in total
cell numbers recruited to the lungs of WT and ISG15/ mice
after influenza A virus infection (data not shown).
We next analyzed the types of cells recruited to the lung
during Sendai virus infection by performing flow cytometric
analysis on cells isolated from lung parenchyma digests. We
found an elevation of neutrophils, inflammatory monocytes,
and NK cells over mock-infected levels by day 3 postinfection
in all strains. However, there were no significant differences
observed between WT, ISG15/, or UbE1L/ mice at 3 or 6
days postinfection (Fig. 5C). The only difference we observed
was a 2-fold increase in inflammatory monocytes in ISG15/
lungs compared to WT mice at day 8 p.i. We observed T-cell
recruitment above mock-infected levels starting at day 6
postinfection, but we observed no differences in CD8 or
CD4 T-cell numbers between genotypes (Fig. 5D). We also
observed similar percentages of cell types recovered from BALF
from WT, ISG15/, and UbE1L/ mice infected with Sendai
virus (data not shown). Based on these findings, we observed
no major differences between the three strains of mice in either
FIG 3 Influenza A virus and Sendai virus replication is not altered in primary tracheal epithelial cultures lacking ISG15 or ISG15 conjugates. Primary murine
trachea epithelial cell cultures were generated from WT, ISG15/, and UBE1L/mice. Cultures were either left unstimulated (A, C, and E) or stimulated with
beta interferon for 24 h (B, D, and F) before infection with influenza B/Yamagata/88 (A and B), influenza A/WSN/33 (C and D), or Sendai (E and F)virus. Titers
were determined by plaque assay in apical medium at various times after infection to evaluate virus replication. Virus growth curves were generated from two
infections performed on different mTEC preparations with a total of 5 to 6 total replicates between the two infections. Panels A and B: *,P	 0.05, Mann-Whitney
test. Panels C to F: *, P	 0.05, Kruskal-Wallis test, followed by Dunn’s posttest.
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the number or the composition of inflammatory cells recruited
to the lung after infection.
During recovery from infection mice lacking ISG15 display
an increase in diseased airways. Although previous studies of
respiratory virus pathogenesis have revealed that immunodefi-
ciency can lead to the spread of virus outside the lung, we were
unable to detect either influenza A virus or Sendai virus by plaque
assay in the kidney, spleen, liver, heart, or brain at day 8 postin-
fection (data not shown) (47). Histological analysis of these or-
gans revealed no pathology outside the lung (data not shown). A
FIG 4 ISG15 does not affect cytokine production after influenza A virus or Sendai virus infection. WT, ISG15/, and UBE1L/mice were infected with 5.0
103 PFU of influenza A/WSN/33 virus (A) or 1.2 106 PFU of Sendai virus (B) i.n. At days 3, 6, and 8 postinfection, mice were sacrificed and BALF was analyzed
for cytokines and chemokines by Bio-Rad multiplex analysis. (C) BALF from Sendai virus-infected mice was analyzed for the levels of alpha interferon by ELISA.
Panels A to C: *, P 	 0.05, Kruskal-Wallis test, followed by Dunn’s posttest, was performed for each time point except for day 8 (panel A), for which a
Mann-Whitney test was used.
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careful histological evaluation of the lung epithelium at day 8
postinfection revealed similar damage in both ISG15/ and
UbE1L/ mice compared to WT mice (data not shown). We
noted that during both influenza A virus and Sendai virus infec-
tion the ISG15/ and UbE1L/ mice succumb to infection at
around days 9 to 10 postinfection (Fig. 1 and 2). Previous charac-
terization of the lung histopathology during influenza A virus and
Sendai virus infection have shown that at this time the airway
epithelium is beginning to repair itself from the damage induced
during the infection (48–50). We therefore hypothesized that
ISG15 may play a role in lung repair after infection.
In order to evaluate the lung pathology during this healing
phase, we decreased the infectious dose of Sendai virus so that only
20% of ISG15/ and UbE1L/ mice succumbed to infection
(Fig. 6A). Interestingly, at this lower dose, while WT mice began to
regain body weight at day 8 postinfection, the ISG15/ and
UbE1L/ mice were delayed in initiating weight recovery (Fig.
6B). At day 11 postinfection both ISG15/ and UbE1L/ mice
had recovered only 75% of their initial body weight compared to
the 85% weight recovery observed in the WT mice. An analysis of
viral loads in the lungs revealed that, similar to the higher dose of
infection, peak virus titers were observed at days 3 and 6 postin-
fection in all genotypes, and by day 11 postinfection all three ge-
notypes of mice had cleared replicating virus (Fig. 6C). At day 3
postinfection, we did note a small increase in viral loads (3-fold)
in ISG15/ mice compared to WT mice. Histological evaluation
of lungs harvested from these mice at day 11 postinfection showed
increased numbers of abnormal small terminal airways in the
ISG15/ mice compared to WT mice (Fig. 5D to H). These ab-
normal airways were either in the form of denuded airways (no
epithelial cells present) or extensive epithelial proliferation that
spills over into adjacent alveoli. Therefore, during recovery from
Sendai virus infection mice lacking ISG15 displayed an increase in
diseased airways.
DISCUSSION
Due to its robust expression after type I interferon stimulation,
ISG15 has long been hypothesized to contribute to the interferon-
FIG 5 Similar numbers and cell populations are recruited to the lungs during Sendai virus infection in the presence or absence of ISG15 conjugation. WT,
ISG15/, and UBE1L/ mice were infected with 1.2 106 PFU of Sendai virus i.n. At days 3, 6, and 8 postinfection, mice were sacrificed, and the lungs were
lavaged and subsequently processed into single cell suspensions. Single cell suspensions of digested lungs (A) and cells from the lavage (B) were analyzed for total
cell number based on hemocytometer counting. (C and D) Cell populations recovered from lung digests were stained for cell surface markers and analyzed by
FACS as described in Materials and Methods. *, P	 0.05, Kruskal-Wallis test, followed by Dunn’s posttest.
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mediated intracellular antiviral response. Supporting this hypoth-
esis, ISG15/mice are more susceptible than WT mice to certain
viral infections, and a number of reports have been published
showing the ability of ISG15 to antagonize replication of viruses in
tissue culture. One way that this inhibition has been shown to occur
is through the ISGylation of viral and host proteins. ISGylation of
human papillomavirus capsid protein has been shown to inhibit
the infectivity of virus that incorporates ISGylated capsid, and
ISGylation of the influenza A virus NS1 protein has been shown
both to inhibit its ability to associate with importin 
 and to affect
its ability to antagonize the interferon response (26, 27, 29). In
addition, hundreds of host proteins are also ISGylated, and these
modifications likely contribute to antagonizing the virus life cycle.
In the case of Ebola virus, ISG15 can inhibit virus-like particle
release by inhibiting the ubiquitin E3 ligase activity of Nedd4 (32,
33). These examples demonstrate the diversity of mechanisms by
which ISG15 can inhibit virus replication.
Although there is now evidence that ISG15 can act as a protec-
tive factor during CHIKV infection by a mechanism that does not
involve inhibition of virus replication, this observation was found
to be mediated by the unconjugated form of ISG15 (22). We re-
port here a novel mode of ISG15-mediated protection from virus
infection. We have shown that similar to its role during influenza
B virus infection, ISG15 protects mice from influenza A virus in a
FIG 6 Infection with Sendai virus at a lower dose reveals increased weight loss and distal airway damage in ISG15/mice. WT, ISG15/, and UbE1L/mice
were infected with 0.6 106 to 1.0 106 PFU of Sendai virus and were monitored for lethality (A) and weight loss (B). (C) Viral loads in the lungs of mice were
analyzed at days 3, 6, 8, and 11 days postinfection by plaque assay. (D to H) Lungs from mice infected with Sendai virus were harvested at 11 days postinfection,
fixed, sectioned, and stained with hematoxylin and eosin. (D) Representative image of a small airway from a mock-infected mouse. (E to G) Representative
images of small airways from a mouse 11 days after Sendai virus infection exhibiting no aberrant disease (E), denudation of epithelium (F), or epithelial
hyperplasia (G). The insets represent an expanded view of a section of epithelium. (H) Stained sections were scored blindly by a pathologist for evidence of
damage to the small terminal airways, including epithelial hyperplasia and denuded airways. Panel C: *, P 	 0.05, Kruskal-Wallis test, followed by Dunn’s
posttest. Panel H: *, P	 0.05, Mann-Whitney test.
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conjugation-dependent manner. However, while ISG15 is impor-
tant for protecting mice from influenza A virus-induced lethality,
we observed no difference in virus burden, suggesting that ISG15
protects mice from influenza A virus and influenza B virus by two
distinct mechanisms. Moreover, unlike its role during CHIKV
infection, ISG15 had no effect on cytokine regulation after influ-
enza A virus infection. We have also shown that this mode of
ISG15-mediated protection does not appear to be unique to influ-
enza A virus infection. Through the evaluation of Sendai virus
pathogenesis in ISG15/ and UbE1L/ mice, we found that
ISG15 conjugation protects mice from Sendai virus by a mecha-
nism that closely resembles the characteristics of ISG15-mediated
protection against influenza A virus infection.
In these two models ISGylation appears to have minimal im-
pact upon viral replication in vitro or in vivo. In the Sendai virus
model, while we did detect a small increase in viral loads in
ISG15/ and UbE1L/ mice compared to WT mice at certain
times, these differences paled in comparison to the magnitude by
which ISG15 restricts influenza B virus replication (24). In addi-
tion, we observed no difference in influenza A virus or Sendai
virus replication in mTECs. It has previously been reported that
ISG15 inhibits the replication of both influenza A virus and Sendai
virus in tissue culture (25–28). The discrepancies between our
findings and previously published data could reflect a difference
between a primary heterogeneous culture of cells and immortal-
ized cell lines. There is precedent for cell type specific effects of
ISG15 on influenza A virus replication, which is now further sup-
ported by the fact that we did not initially detect a difference in
influenza B virus replication in ISG15/ embryonic fibroblasts
(21, 25). It is also possible that these discrepancies reflect a differ-
ence in the function or specificity of human and murine ISG15.
Such species specificity has been reported with respect to the in-
fluenza B virus NS1 protein (B/NS1), which can bind to and in-
hibit conjugation of human and primate ISG15 but not mouse
ISG15 (51, 52). Further studies will be needed to explain these
discrepancies.
Previously it was shown that influenza A virus NS1 protein is
ISGylated in A549 cells. In this system, this modification ac-
counted for most of the antiviral activity of ISG15 against influ-
enza A virus (26, 27). One potential explanation for ISG15 not
affecting influenza A virus or Sendai virus replication in our sys-
tem is that viral proteins are not being ISGylated. We have found
that expression of the murine ISG15 conjugation system and in-
fluenza virus proteins in 293T cells can result in the ISGylation of
viral proteins (data not shown). However, we do not know
whether these proteins are also modified in the respiratory epithe-
lium during the course of infection. If influenza A virus or Sendai
virus proteins are modified during infection, our data would sug-
gest that these modifications do not have a significant effect on
replication. However, such modifications could still play a role
during pathogenesis in vivo through the regulation of other host
responses such as cell death or antigen presentation. This impor-
tant line of research could shed more light on additional mecha-
nisms by which ISG15 regulates pathogenesis.
A surprising observation from these studies is the differential
effects that ISG15 has on influenza A and influenza B virus repli-
cation. However, this finding is not entirely unexpected. The func-
tion of ISG15 conjugation during influenza A virus and influenza
B virus infection in vivo correlates with the effects of type I inter-
ferons on these viruses in vivo. IFNAR/ mice display dramati-
cally elevated viral loads compared to WT mice during influenza B
virus infection (24). Whereas a number of studies have found
either no difference or only small differences in virus replication
and virus clearance in IFNAR/mice during influenza A virus or
Sendai virus infection (53–56). As mediators of the interferon
response, ISGs might then also be expected to have different ef-
fects on influenza A virus compared to influenza B virus. In addi-
tion, studies of the NS1 protein of influenza A and B viruses have
suggested that ISG15 might play distinct roles during these infec-
tions. B/NS1 binds to human and primate ISG15, resulting in the
inhibition of ISG15 conjugate formation (52). Influenza A/NS1
virus does not bind to ISG15; however, unlike B/NS1, A/NS1 has a
greater capacity to inhibit the interferon response and the induc-
tion of ISGs, including ISG15, in infected cells (51). This suggests
either that ISG15 has imposed a different evolutionary pressure on
influenza B virus compared to influenza A virus or that influenza
A virus has adapted to the evolutionary pressure of ISG15 through
an alternative mechanism.
There could be a number of reasons to explain the differential
effect of ISG15 on influenza A and B viral infection. As noted
previously, these viruses may have differential sensitivity to the
effects of IFNs due to the immune evasion strategies that they
employ. In addition, influenza A and B viruses may use distinct
cellular pathways during their replication cycles which can be dif-
ferently regulated by ISG15. Finally, it is interesting that a com-
parison of the lysine content of influenza A/WS/1933, A/PR8/
1934, and A/California/2009 viruses to that of influenza B/Lee/
1940, B/Yamagata/1988, and B/Victoria/1987 viruses reveals that
the influenza B virus proteome contains an35% increase in total
lysine residues compared to influenza A virus. It is tempting to
speculate that this might render influenza B virus more suscepti-
ble to potentially detrimental effects of viral protein ISGylation.
Further research into influenza B virus biology will be needed in
order to explain these differences in the effects of ISG15 and in-
terferon on the pathogenesis of influenza A and influenza B vi-
ruses.
In both influenza A virus- and Sendai virus-infected mice we
observed lethality at around 9 to 10 days postinfection, a time
when mice are clearing the acute viral infection, beginning to re-
gain weight, and beginning to repair the airway epithelium. By
lowering the infectious dose of virus and allowing a significant
number of the ISG15/ mice to survive infection, we observed a
difference in the ability of the ISG15/ mice to recover weight,
and histological examination of the lungs revealed increased dis-
ease in the smaller airways of the lung in the ISG15/mice. These
histological changes noted in the airway epithelium are consistent
with previous reports of Sendai virus pathogenesis (57, 58). One
study evaluating the disease susceptibility of different mouse
strains to Sendai virus found that although resistant and suscep-
tible mouse strains have dramatically different 50% lethal dose
titers, little difference in viral loads or viral clearance was observed
between mouse strains over the course of infection (58). The in-
creased susceptibility to Sendai virus induced lethality appeared to
correlate with an increase in the number of airways exhibiting
delayed re-epithelialization or epithelial hyperplasia.
It is not clear whether the increase in diseased airways we ob-
served in ISG15/ mice during Sendai virus infection is a result
of increased damage, a defect in the wound repair response, or
some combination of both. Different functions that have been
previously described for ISG15 could support a role for ISG15 in
Morales et al.
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either process. It has been shown that ISG15 inhibits apoptosis
through ISGylation of filamin B and that ISG15/ peritoneal
macrophages have a reduced phagocytic capacity (59, 60). Either
increased apoptosis or a decreased capacity to clear apoptotic bod-
ies might result in increased damage in the distal airways of
ISG15/mice. A number of viruses have been reported to induce
apoptosis, and it is thought that in some cases this might facilitate
virus spread (61). Thus, an inability to control apoptosis or clear
apoptotic debris might also account for the small differences in
viral load observed in ISG15/ mice during Sendai virus infec-
tion in vivo.
Bronchial epithelial healing after Sendai virus infection in-
volves the loss of epithelial differentiation markers on cells after
infection, cell proliferation and migration to repopulate the dam-
aged airways, and differentiation of cells into the proper epithelial
cell types (48). Although it is unclear whether ISG15 plays a role in
these processes, one study has shown that the knockdown of
ISG15 or UbCH8 in a breast cancer cell line resulted in a reorga-
nization of the actin cytoskeleton and the decreased ability of a cell
monolayer to close a scratch wound in tissue culture (62). There-
fore, it is possible that ISG15 could play a role in the ability of the
bronchial epithelium to recover after infection. There have been
several recent studies demonstrating both cell-intrinsic and cell-
extrinsic mechanisms that are needed to maintain proper airway
epithelial integrity. Mice lacking cellular inhibitor of apoptosis 2
(cIAP2) were recently shown to exhibit increased lethality after
influenza A virus infection without any observed difference in
virus burden or in the immune response to infection (63). Rather,
these cIAP2 mice displayed increased necroptosis in the airway
epithelium. Innate lymphoid cells have also been reported to pro-
tect mice from influenza A virus infection by a manner that is
independent of controlling virus replication. These cells secrete
amphiregulin, which helps to promote survival by increasing air-
way epithelial integrity (64). Additional studies will be needed to
determine whether ISG15 contributes to these responses.
ISG15 is strongly upregulated after type I interferon stimula-
tion and viral infection, and, in many cases, it protects the host
from viral induced morbidity and mortality. Type I interferons
have clearly been shown to inhibit virus replication in tissue cul-
ture. However, the role of type I interferons during respiratory
virus infections in vivo is less well understood, and recent findings
suggest that the more important role of type I interferons during
these infections might be to modulate the immune response to
regulate tissue damage and morbidity (53, 55). Similarly, our re-
sults suggest that while ISG15 conjugation is capable of antago-
nizing replication of some viruses, it also plays a role in some
aspect of disease tolerance against influenza A virus and Sendai
virus infection in vivo. Thus, it will be important in the future to
more thoroughly evaluate the nonantiviral roles that ISG15 con-
jugation plays in vivo and how these functions might affect disease
tolerance and outcome in mice after viral infection.
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